Detalhe da pesquisa
1.
Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas.
Clin Cancer Res
; 29(8): 1423-1428, 2023 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36729110
2.
Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib.
JCO Precis Oncol
; 52021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34250398
3.
Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor).
Cancer
; 116(9): 2258-65, 2010 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20187095